Physician profile
Nathan Cox
NPI 1508391780
$7,428.78
in general payments reported to CMS, 2019-2025
23 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $25.73 · 2021: $390 · 2022: $1,736 · 2023: $1,724 · 2024: $1,390 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,569 · Education: $51.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,568.71 |
| Education | $51.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,639.54 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $836.25 | 2019-2025 | |
| Leo Pharma INC. | $719.68 | 2021-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $637.87 | 2020-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $613.98 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $515.17 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $380.84 | 2022-2025 | Sotyktu |
| Pfizer INC. | $363.10 | 2022-2025 | |
| Ucb, INC. | $356.46 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $330.29 | 2023-2025 | Nemluvio |
| Incyte Corporation | $289.73 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $129.49 | 2021-2025 | |
| Allergan, INC. | $120.47 | 2019-2022 | |
| Janssen Biotech, INC. | $96.54 | 2022-2024 | Simponi, Simponi Aria, Stelara |
| Biofrontera INC. | $72.69 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $67.49 | 2022-2023 | Poteligeo |
| Novartis Pharmaceuticals Corporation | $57.91 | 2025 | |
| Merz North America, INC. | $57.57 | 2023 | Xeomin |
| Organon LLC | $56.83 | 2025 | |
| Stemline Therapeutics INC. | $24.74 | 2022 | |
| Arcutis Biotherapeutics, INC. | $23.21 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.26 | 2024 | Siliq, Duobrii |
| Genentech USA, INC. | $17.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.